URGN Company Profile and Key Details

Q: Who are the executives of URGN?

Mr. Jason Drew SmithGen. Counsel, Chief Compliance Officer & Corporation Sec.Dr. Marina KonortyExecutive Vice President of R&D and Technical OperationsMs. Elizabeth A. BarrettPres, Chief Executive Officer & DirectorMr. James Ottinger R.ph.Executive Vice President of Regulatory Affairs & QualityMr. Dong KimChief Financial OfficerEric Van ZantenSenior Director of CommunicationsDr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorMr. Jeffrey Bova M.B.A.Chief Commercial OfficerDr. Mark P. Schoenberg M.D.Chief Medical OfficerVincent I. PerroneSenior Director of Investor RelationsMr. Eric Van ZantenVice President of Investor & PR

NASDAQ : URGN

UroGen Pharma

$21.18

0.51+2.47%

At Close 4:00 PM

60.56

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

UroGen Pharma Ltd. (URGN) stock surged +2.47%, trading at $21.18 on NASDAQ, up from the previous close of $20.67. The stock opened at $20.44, fluctuating between $20.13 and $21.23 in the recent session.

Stock Snapshot

20.67

Prev. Close

991.41M

Market Cap

20.125

Day Low

-6.1

P/E Ratio

-3.47

EPS (TTM)

-2.12

Cash Flow per Share

20.44

Open

46.81M

Number of Shares

21.2304

Day High

80.04%

Free Float in %

-1.8

Book Value

506.27K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 26, 2026	20.67	21.36	19.91	21.18	515.54K
Feb 25, 2026	21.04	21.90	20.40	20.67	626.14K
Feb 24, 2026	20.89	21.39	20.61	20.75	386.67K
Feb 23, 2026	20.79	21.56	20.32	20.92	334.74K
Feb 20, 2026	21.50	22.02	20.76	21.07	577.17K
Feb 19, 2026	22.19	22.50	21.28	21.80	1.4M
Feb 18, 2026	20.67	22.34	20.46	22.27	892.93K
Feb 17, 2026	19.72	20.82	19.45	20.60	807.55K
Feb 13, 2026	20.26	21.62	19.95	20.10	786.72K
Feb 12, 2026	21.19	21.20	19.65	20.21	351.45K
Feb 11, 2026	21.68	22.01	20.20	21.14	588.66K
Feb 10, 2026	21.90	22.25	21.45	21.67	305.37K
Feb 09, 2026	21.24	22.04	20.94	21.90	305.23K
Feb 06, 2026	20.68	21.77	20.68	21.35	739.91K
Feb 05, 2026	20.57	22.21	20.38	20.52	1.03M
Feb 04, 2026	20.25	21.38	19.91	20.71	1.01M
Feb 03, 2026	19.51	20.16	19.13	20.00	706.71K
Feb 02, 2026	19.49	19.96	19.21	19.70	455.87K
Jan 30, 2026	20.58	20.85	19.38	19.61	649.01K
Jan 29, 2026	21.13	21.64	20.23	20.69	410.91K

Contact Details

Princeton, NJ 08540

United States

https://www.urogen.com 646 768 9780

About Company

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Stock Peers

ARGX

-45.42-5.56%

argenx SE$771.53 REGN

-13.49-1.72%

Regeneron Pharmaceuticals, Inc.$770.79 UTHR

-31.5-5.89%

United Therapeutics Corporation$503.60 VRTX

-2.92-0.60%

Vertex Pharmaceuticals Incorporated$480.13 MDGL

10.84+2.49%

Madrigal Pharmaceuticals, Inc.$445.85 PRAX

-7.08-2.04%

Praxis Precision Medicines, Inc.$340.47 ALNY

4.1+1.25%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

3.86+1.42%

Krystal Biotech, Inc.$276.36 ASND

0.99+0.43%

Ascendis Pharma A/S$228.99

Company Overview

UroGen Pharma Ltd. (NASDAQ:URGN) closed at $21.18 USD, gaining $0.51 (2.47%) from the previous close of $20.67. The stock is currently mid-range between its 52-week high and low $3.42 and $30.00. With a market capitalization of about $991.41 million, UroGen Pharma Ltd. is classified as a small-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 742.75 thousand shares, volume is running light vs its 52-week average. Headquartered in Princeton, NJ, UroGen Pharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Elizabeth A. Barrett, the company employs approximately 234 people and listed since May 04, 2017. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 1.62%, SMA50 -1.01%, SMA200 16.58%). The stock’s 14-day RSI is 51.02 (neutral), while the ATR of 1.36 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.4% below its high and over 519.3% above its low. Average 10-day trading volume of 692.23 thousand shares is in line with the 3-month average of 704.47 thousand, indicating normal recent market interest.

Valuation Metrics

UroGen Pharma Ltd. trades at a P/E ratio of -8.85, slightly below the S&P 500 average, with a price-to-sales ratio of 13.67 and a price-to-book ratio of -8.79 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.16, also below market averages.

Dividend & Fair Value

UroGen Pharma Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.44. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

UroGen Pharma Ltd. generated EPS of -$3.46 over the past year. Five-year average earnings growth is 10.39%. The latest quarter delivered EPS of -$0.69. The next quarter is forecast at -$0.50. Next year's EPS is expected at $27.33. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $10.00. The high target offers 159.68% upside. The low target suggests -52.79% downside. The mean target is $31.89. This offers 50.57% upside. UroGen Pharma Ltd. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -3.63%. The prior quarter beat by 28.05%. Over the last six quarters, Apple has recorded several small beats. These include 10.63% in August 13, 2024.

Shareholding & Insider Activity

UroGen Pharma Ltd. has 46.26 million shares outstanding. The public float is 37.03 million shares, elevated short interest at 15.41% of float. This equals 7.02 million shares. The short ratio is 6.63 days. Institutional investors hold 101.78% of the float. Insiders own 3.85%. ProQuest Investments IV, L.P. holds 1.24 million shares, Barrett Elizabeth A. has 300.98 thousand shares and Schoenberg Mark has 144.98 thousand shares. Over the past six months, insider transactions show net selling. They sold 19.89 thousand shares across 6 transactions.

Financial & Profitability Overview

Over the trailing twelve months, UroGen Pharma generated $82.71M in revenue, or $2.87 per share. Gross margin was 88.68%, operating margin -79.23%, and net profit margin -123.61%. Returns are negative, with ROA at -57.34% and ROE at 156.79%.
On valuation metrics, UroGen Pharma trades at a P/E of -8.85, P/S of 13.67 and P/B of -8.79. The current ratio is 3.99 and quick ratio is 3.79. Operationally, the company’s inventory turnover is 0.97 and cash conversion cycle is 11.91 days. Debt-to-equity is -1.13, supported by a cash flow-to-debt ratio of -1.06.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, UroGen Pharma posted revenue of $82.71M, down slightly from $64.36M in the prior quarter. Gross profit was $73.35M (margin 88.68%). Operating income was - $65.54M (margin -79.2%). Net income was- $102.24M (EPS - $3.55).
The company ended the quarter with $137.79M in cash and short-term investments, a total debt of $100.21M, and net debt of $4.39M. Total assets were $178.31M, with equity of - $65.21M. Financials further reflected weakness, with operating cash flow of - $76.38M, free cash flow of - $76.57M, and capital expenditures of - $194.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that UroGen Pharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.28%, with price expected at $21.24 by March 12, 2026, within a range of $19.87 to $22.45 3-Month Outlook: Projected fall of -52.69%, reaching $10.02 by May 27, 2026, with a range of $9.53 to $10.43. 1-Year Outlook: Projected gain of 6.23%, with price at $22.50 by February 26, 2027, within a range of $20.95 to $23.81.

Key Takeaways

UroGen Pharma Ltd. (NASDAQ:URGN) shares are down -17.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows UroGen Pharma Ltd. trading at a premium to the broader market with a P/E of -8.85. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.42, suggesting 81.4% upside. Our AI forecast model points to short-term strength (0.28% over two weeks), a medium-term fall (-52.69% over three months), and a longer-term gain (6.23% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current UroGen Pharma Ltd. (URGN) stock price?

UroGen Pharma Ltd. (NASDAQ: URGN) stock price is $21.18 in the last trading session. During the trading session, URGN stock reached the peak price of $21.23 while $20.13 was the lowest point it dropped to. The percentage change in URGN stock occurred in the recent session was 2.47% while the dollar amount for the price change in URGN stock was $0.51.

URGN's industry and sector of operation?

The NASDAQ listed URGN is part of Biotechnology industry that operates in the broader Healthcare sector. UroGen Pharma Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of URGN?

Mr. Jason Drew Smith
Gen. Counsel, Chief Compliance Officer & Corporation Sec.
Dr. Marina Konorty
Executive Vice President of R&D and Technical Operations
Ms. Elizabeth A. Barrett
Pres, Chief Executive Officer & Director
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Mr. Dong Kim
Chief Financial Officer
Eric Van Zanten
Senior Director of Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Eric Van Zanten
Vice President of Investor & PR

How URGN did perform over past 52-week?

URGN's closing price is 519.3% higher than its 52-week low of $3.42 where as its distance from 52-week high of $30.00 is -29.4%.

How many employees does URGN have?

Number of URGN employees currently stands at 234.

Link for URGN official website?

Official Website of URGN is: https://www.urogen.com

How do I contact URGN?

URGN could be contacted at phone 646 768 9780 and can also be accessed through its website. URGN operates from 400 Alexander Park, Princeton, NJ 08540, United States.

How many shares of URGN are traded daily?

URGN stock volume for the day was 506.27K shares. The average number of URGN shares traded daily for last 3 months was 742.75K.

What is the market cap of URGN currently?

The market value of URGN currently stands at $991.41M with its latest stock price at $21.18 and 46.81M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	234
Beta	1.36
Sales or Revenue	$82.71M
5Y Sales Change%	39.064%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

URGN Company Profile and Key Details

UroGen Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics